| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |